Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01527955
Other study ID # IRB Project#081197
Secondary ID
Status Completed
Phase N/A
First received February 2, 2012
Last updated February 6, 2012
Start date September 2008
Est. completion date June 2011

Study information

Verified date February 2012
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine how effective Kelee meditation is in improving stress, anxiety, and depression.


Description:

The Kelee and Kelee meditation (KM) were developed and founded by Ron W. Rathbun. KM is a unique and distinctive form of meditation that is easy to learn and requires only about 10 minutes twice a day to perform. The goal and discipline of KM is the development of one-pointed stillness of mind. To better comprehend how KM is effective in reducing stress, anxiety, and depression, one must understand the difference between concentration and meditation, and the basic principles of the Kelee. Experiencing and understanding the distinction between brain function and mind function are of vital importance in KM. Brain function is associated with the tension-based, intellectual, thinking process and the five physical senses whereas mind function is associated with the relaxation-based, experiential, mental feeling process, self-awareness, and clear perception. Performing KM leads to the calming of brain function and opening to the experience of mind function. With continued practice, persistence, and patience, the practitioner can begin to learn on his own how to examine and understand (ie, troubleshoot) his own thoughts and feelings from a calm, clear internal space that is free from the negative chatter and preconception associated with the brain. This increases self-awareness of the presence of internalized compartments (misperceptions of life that exist as negative thoughts and/or feelings) and the practitioner begins to develop clarity of perception. Clear perception allows one to begin the process of detachment from internalized compartments, which occurs through the cessation of looping followed by the processing of compartments. As each negative compartment dissipates, the practitioner experiences a subtle, but cumulative, corresponding improvement in stress, anxiety, and depression. When the flow of the Kelee is allowed to be, there is balance between the thinking and the feeling process leading to overall well-being, which leads to improved self-efficacy and reinforces the repetition of KM.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date June 2011
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Documented HIV-1 infection

- Ages 18 to 65

- Experiencing some level of stress, anxiety, or depression

- No current use of other meditation practices or holistic modalities

Exclusion Criteria:

- Non-English readers or speakers

- Hearing-impaired

- Low literacy below 5th grade reading and comprehension level

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Other:
Kelee Meditation
The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.

Locations

Country Name City State
United States Being Alive San Diego San Diego California
United States University of California, San Diego Medical Center San Diego California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Total Score of Depression, Anxiety, and Stress Scales-42 (DASS-42) The DASS is a set of 3 self-report scales designed to measure the negative emotional states of depression, anxiety and stress and to further the process of defining, understanding, and measuring the ubiquitous and clinically significant emotional states usually described as depression, anxiety and stress. Each of the 3 DASS scales contains 14 items. Subjects are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week. Scores for Depression, Anxiety and Stress are calculated by summing the scores for the relevant items. From Week 0 (baseline) to Week 12 No
Secondary Change in Depression Subscale Score of DASS-42 The Depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest/involvement, anhedonia, and inertia. From Week 0 (baseline) to Week 12 No
Secondary Change in Anxiety Subscale Score of DASS-42 The Anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect. From Week 0 (baseline) to Week 12 No
Secondary Change in Stress Subscale Score of DASS-42 The Stress scale is sensitive to levels of chronic non-specific arousal. It assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive and impatient. From Week 0 (baseline) to Week 12 No
Secondary Change in Total Score of Beck Depression Inventory-II (BDI-II) The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. The cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; and 29-63: severe depression. Higher total scores indicate more severe depressive symptoms. From Week 0 (baseline) to Week 12 No
Secondary Change in Total Score of Beck Anxiety Inventory (BAI) The BAI consists of 21 questions about how the subject has been feeling in the last week, expressed as common symptoms of anxiety. Each answer is scored on a scale value of 0 to 3. The cutoffs are as follows: 0-7: minimal anxiety; 8-15: mild anxiety; 16-25: moderate anxiety; and 26-63: severe anxiety. From Week 0 (baseline) to Week 12 No
Secondary Change in Total Score of Perceived Stress Scale-10 (PSS-10) The Perceived Stress Scale (PSS) is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items. Higher total scores suggest a higher degree of perceived stress. From Week 0 (baseline) to Week 12 No
Secondary Change in Global Severity Index (GSI) of the Symptom Checklist-90-Revised (SCL-90-R) The Symptom Checklist-90-R (SCL-90-R) instrument helps to evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The Global Severity Index (GSI) is the summary of the test and is designed to measure overall psychological distress. From Week 0 (baseline) to Week 12 No
Secondary Change in Mental Component Summary (MCS) of the Short Form-36 Health Survey (SF-36) The SF-36 is a short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures [Physical Component Summary (PCS) and Mental Component Summary (MCS)] and a preference-based health utility index. From Week 0 (baseline) to Week 12 No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A